Foods for the Treatment of Malnutrition

Published: 

Summary of Conference Presentation

At the Dublin conference on Emergency Supplementary Feeding (February 18 to 21, 1997), reported on in the last issue of Field Exchange, Prof. Mike Golden of Aberdeen University gave a succinct overview of his work in developing suitable foods for the treatment of malnutrition. His main point was that "low recovery rates that are often reported in therapeutic and supplementary feeding programmes may be attributable to fundamental physiological changes and nutrient deficiencies that occur in malnutrition but are not adequately addressed by diets currently in use". His research has shown that the most appropriate diets for treating malnutrition should do two things:

  • make up for nutrients that are normally stored in the body (Type 1 nutrients), e.g. iron, vitamin A, selenium, but have been depleted
  • provide in higher than normal quantities in the severely malnourished, nutrients which cannot be stored and need to be consumed on a daily basis (Type 2 nutrients), e.g. amino acids, sodium and potassium.

Three feeding products have now been developed as a result of this work:

F75 (Phase 1 milk) is designed for use in the initial phase of the recovery process from severe malnutrition when metabolism is abnormal. The milk is modified to reduce the risk of diarrhoea. It has a lower osmolarity, sodium, fat and protein content and a higher carbohydrate content than F100. ACF is currently assessing this product in field.

F100 (Phase 2 milk) is a high energy milk with added minerals and vitamins. It is intended for the treatment of severely malnourished children once their condition has been stabilised (in phase 2 of therapeutic feeding) and is designed to maximise weight gain and reduce mortality rates. Evaluations of this product in ACF feeding centres have shown mortality and weight gain rates that are comparable to those achieved in the more controlled environment of a metabolic ward.

SP450 is a porridge fortified with vitamins and minerals. It can be used in phase 2 of therapeutic feeding and in supplementary feeding programmes. It is suitable for all ages. The product has been assessed in a number of ACF supplementary feeding programmes. Initial findings are summarised in the table below.

Diet Recovered Defaulted Death Weight gain per kg per day
Porridge 51% 39% 1% 1 gr/kg/day
SP450 81.9% 9% &nbsp 5 gr/kg/day

 

Issues and Challenges:

  • F100 is relatively expensive at US$3,000 per tonne. However, a comparative economic evaluation, which would need to take into account the slower rate of recovery in children given less appropriate foods, could show that F100 is actually more cost-effective
  • Future developments will focus on designing a "take home" equivalent of F100 to facilitate home treatment of severe malnutrition. This may be of use for programmes in poor security situations.
  • F100 is approved and recommended by UNICEF for therapeutic feeding. Stocks of F100 will be stored in countries where therapeutic nutrition programmes are operational.
  • SP450 is now being produced in Kenya at US$ 1000 per tonne (compared to US$600 for normal porridges). Initial findings have shown that this locally made porridge can achieve up to five times the weight gain of that attained using other local porridges.

For further information contact: Professor Mike Golden, Department of Medicine and Therapeutics, University of Aberdeen, Forresterhill, AB9 2ZD. Tel. No. +44 1 224 681818 e-mail: m.golden@abdn.ac.uk

In 1989 Professor Mike Golden developed and tested a prototype feed for severely malnourished children in a metabolic ward in Jamaica. After some adjustments to the formula and acceptance by a number of UN agencies and NGOs a company called Nutriset took the formula and started to produce it in pre-packaged sachets which they called 'therapeutic milk'. Action Contra la Faim started to use the product immediately and reported that it was a great success. A large number of other agencies followed suit. Specifications for the feed are now published and in the public domain so that any manufacturer with the ability and adequate quality control procedures can produce it. The company Compact in Denmark has also started to manufacture the same formula so that it is now available commercially from at least two sources. F100 (the preferred name for the complete formula), 'therapeutic milk' and the Nutriset and Compact products are all the same basic formula.

Imported from FEX website

Published 

About This Article

Article type: 
Original articles

Download & Citation

Recommended Citation
Citation Tools